moa of semaglutide Spotlight on the Mechanism of

[DOI] [PubMed] [Google Scholar] 4.Economic impacts of overweight and obesity: current and future estimates for 161 countries

The risk appears to be rare, and the evidence is not fully settled

Always read the leaflet or ask your doctor/pharmacist for an explanation

In a statement, Novo Nordisk, maker of the GLP-1 drug semaglutide, noted, For Wegovy specifically, animal studies suggest there may be risks to the fetus, and weight loss during pregnancy offers no benefit and may cause harm

Wegovy is not known to be an addictive substance, so you may not experience traditional drug withdrawal symptoms like anxiety, tremors, or cravings for the drug

This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you may receive from your healthcare provider